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ABSTRACT 
 
A STUDY ON THE EFFECTS OF ANDROGRAPHIS  PANICULATA 
(HEMPEDU BUMI) ON SERUM PROTEIN C, PROTEIN S ACTIVITY AND 
FASTING BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS. 
 
Background and Objectives 
 
Patients with type 2 diabetes mellitus (DM) show enhanced activation of the blood 
coagulation system and decrease level of natural anticoagulant such as protein C and 
protein S. This is believed to contribute to the high incidence of premature 
atherosclerosis attributable to myocardial infarction, cardiovascular disease and 
peripheral vascular disease in diabetic patients. Andrographis paniculata (Hempedu 
bumi) has been well known to have blood sugar lowering properties in diabetes patients 
and has been used by local Malaysians as an alternative to current oral hypoglycaemic 
agents. With the benefit of its blood sugar lowering properties it is hoped that 
Andrographis paniculata may also increases level serum protein C and protein S in 
diabetic patients, thus reducing the risk of atherosclerotic disease. This study was 
conducted to determine the changes in fasting blood sugar levels and to assess the 
changes in serum protein C and protein S activity following oral administration of 
Andrographis  paniculata among type 2 diabetes mellitus patients in Hospital Universiti 
Sains Malaysia (HUSM) Diabetic Medical Clinic.  
  
Methodology 
 
This is an open-labelled, randomised treatment versus control study which was 
conducted among type 2 diabetes mellitus patient on follow up at the Hospital 
Universiti Sains Malaysia (HUSM) Diabetic Medical Clinic from August 2010 till 
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November 2010. A total of thirty four subjects were recruited in this study. Of this, 17 
were randomly given the study medication; two tablets each containing 250 mg of 
Andrographis paniculata for two weeks duration while the other 17 patients were 
allowed to continue with their previous medication without any alteration. Fasting blood 
glucose (FBG), serum protein C and protein S, blood samples were taken at baseline 
and after two weeks intervention for both groups.  
Results 
 
A total number of 34 patients were involved in this study. The mean age was 55.2 ± 9.8 
years. The baseline HbA1c was 9.2% ± 2.4 % in both groups. The mean fasting blood 
sugar during pre intervention in the control group was 8.6 mmol/L ± 3.7 while in 
treatment group is 9.1 mmol/L ± 5.0 and post treatment, the mean fasting blood sugar 
was 8.3mmol/L ±2.9 and 9.3 mmol/L ± 4.0 respectively.  The mean of protein C in the 
pre intervention for control group was   117.2 %± 17.3 and in the treatment group was 
125.1 % ± 21.3. Post intervention mean protein C in the control group was 121.1 % ± 
25.4 and in the treatment group is 125.9 % ± 18.9. The mean protein S in the pre 
intervention for control group was 202.4 % ± 128.0 and for treatment group is 135.4% 
± 30.1 while in the post intervention mean for control group was 208.3 % ± 129.5 and 
in the treatment group 134.1 % ±25.3. The mean difference of fasting blood sugar, 
protein C and protein S between pre and post intervention for both groups were 
statistically not significant. 
 
Conclusion 
Our study demonstrated that generally the blood sugar control among type 2 diabetic 
patients is still poor with mean HbA1c of 9.2 % ± 2.4. There were no significant 
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changes in mean serum fasting blood glucose, protein C and protein S for pre and post - 
treatment of oral administration of 500 mg of Andrographis paniculata for two weeks 
duration in the treatment group when compared to control group. These findings were 
probably related to inadequate dose of Andrographis paniculata since there was no 
study of bioequivalence in this study and also inadequate study duration to produce 
desirable effects in this study. 
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ABSTRAK 
KAJIAN MENGENAI KESAN HEMPEDU BUMI KE ATAS AKTIVITI 
PROTIN C, PROTIN S DAN PARAS GULA PUASA  DI KALANGAN PESAKIT 
KENCING MANIS DIABETES MELLITUS JENIS KE-2.  
Latar Belakang dan Objektif 
Pesakit kencing manis jenis kedua menunjukkan pengaktifan system pembekuan darah 
dan kerendahan tahap antikoagulasi semulajadi dalam darah seperti protin C dan protein 
S. Ini dipercayai meningkatkan insiden aterosklerosis pramatang dan mengakibatkan 
penyakit kardiovascular serta penyakit salur darah periferi di kalangan pesakit kencing 
manis. Hempedu bumi dikenalpasti dapat menurunkan paras gula dalam darah 
dikalangan peakit kencing manis dan telah digunakan oleh penduduk di Malaysia 
sebagai alternatif kepada ubat-ubatan menurunkan paras gula dalam darah. Dengan itu, 
diharapkan hempedu bumi dapat meningkatkan aktiviti serum protin C dan protin S dan 
sekaligus mengurangkan  risiko penyakit aterosklerosis. Kajian ini ingin menilai 
perubahan dalam paras gula dalam darah ketika berpuasa, aktiviti protin C dan protin S 
selepas pengambilan hempedu bumi atau “Andrographis  paniculata” di kalangan 
pesakit kencing manis jenis kedua yang mendapat rawatan di Klinik Diabetik Hospital 
Universiti Sains Malaysia (HUSM). 
Metodologi 
Ini adalah kajian rawatan aktif versus control dimana pesakit serta doktor tahu akan 
jenis ubat yang diberi yang dijalankan di kalangan pesakit kencing manis jenis kedua. 
Mereka mendapat rawatan susulan di Klinik Diabetik Hospital Universiti Sains 
Malaysia dari Ogos 2010 hingga November 2010. Seramai 34 subjek telah diambil 
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untuk kajian. Seramai 17 orang subjek telah diberi Andrographis paniculata ( Hempedu 
bumi) untuk tempoh dua minggu, dan seramai 17 pesakit dibenarkan mengambil ubat-
ubatan diabetes yang telah sedia digunakan sebelum ini. Darah untuk paras gula semasa 
puasa, protein C dan protein S diambil pada permulaan dan pada penghujung kajian 
untuk kedua-dua kumpulan. 
 
Keputusan 
Seramai 34 orang pesakit terlibat dalam kajian ini. Purata umur untuk semua pesakit 
adalah 55.2 ± 9.8 tahun. Purata permulaan HbA1c untuk semua pesakit  adalah  9.2 % ± 
2.4 %. Purata untuk darah gula puasa sebelum intervensi dan selepas intervensi dalam 
kumpulan kontrol adalah 8.6 mmol/L ± 3.7 dan 8.3 mmol/L ± 2.9. Purata darah gula 
puasa dalam kumpulan intervensi sebelum dan selepas intervensi adalah 9.1 mmol/L ± 
5.0 dan 9.3 mmol/L ± 4.0. 
Purata protin C semasa sebelum intervensi untuk kumpulan kontrol adalah 117.2 % ± 
17.3 dan dalam kumpulan rawatan adalah 125.1 % ± 21.3. Semasa selepas intervensi, 
purata protin C dalam kumpulan kontrol adalah 121.1 % ± 25.4 dan dalam kumpulan 
rawatan adalah 125.9%  ± 18.9. Purata protein S semasa sebelum intervensi adalah 
202.4 % ± 128.0 dalam kumpulan kontrol  dan 135.4%  ± 30.1 di dalam kumpulan 
intervensi. Semasa selepas intervensi, purata protein S dalam kumpulan kontrol adalah 
208.3% ± 129.5 dan 134.1% ± 25.3 dalam kumpulan intervensi. Tiada perbezaan yang 
nyata dalam perubahan darah semasa puasa, protin C dan protin S antara sebelum dan 
selepas intervensi didalam kedua-dua kumpulan kontrol dan rawatan. 
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Kesimpulan 
Kajian ini menunjukkan secara amnya kawalan gula di kalangan pesakit kencing manis 
jenis ke dua adalah tidak memuaskan dengan purata HbA1c sebanyak 9.2 % ± 2.4. 
Tiada perubahan yang nyata  dalam perubahan darah gula puasa, protein C dan protein 
S sebelum dan selepas intervensi dua minggu menggunakan 500 mg Andrographis 
paniculata. Keputusan ini mungkin boleh disebabkan dose Hempedu bumi yang tidak 
cukup disebabkan tiada kajian bioequivalen ke atas ubatan ini dan mungkin jarak masa 
kajian selama dua minggu tidak culup untuk memberikan keputusan yang diharapkan 
dalan kajian ini.  
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1.0 INTRODUCTION 
 
1.1 BACKGROUND OF DIABETES MELLITUS 
 
Diabetes mellitus (DM) was likely first described about 3500 years ago and the first 
case reported for diabetes was in the year of 3rd Dynasty Egyptian physician in 1555 
(Gemmill, 1972). Since then a lot has been studied about nature of the disease, types of 
the disease and its complications.   
 
DM has been primarily regarded as a disorder of glucose metabolism and recently has 
been viewed as a constellation of metabolic disturbances, including abnormalities of 
carbohydrate metabolism, adipose storage, lipid metabolism, and protein biochemistry. 
WHO criteria divided DM as Type 1 diabetes mellitus (T1DM) which is characterised 
by a lack of insulin production. Type 2 diabetes mellitus (T2DM) or formerly called 
non-insulin-dependent or adult-onset diabetes is caused by the body’s ineffective use of 
insulin. The American Diabetes Association (ADA) Expert Committee has also 
introduced as in addition to type 1 and type 2 diabetes mellitus, "specific types" of 
diabetes are identified: gestational diabetes and secondary diabetes. Gestational diabetes 
mellitus (GDM) is defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy (Metzger BE and Coustan DR, 1998). 
 
The incidence of DM is increasing rapidly as a result of aging and an ever more obese 
population (Ali H. Mokdad et al., 2001). Indeed, between 2000 and 2010, the number of 
patients with DM is expected to increase by 23 % in the United States and 46% around 
the world. The International Diabetes Federation (IDF) predicts by year 2025 the South 
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East Asia region would have an estimated diabetes prevalence of 7.5 % and IGT 
prevalence of 13.5 % (IDF Diabetes Atlas 2003). 
 
In Malaysia, the number of people with diabetes is increasing with significantly high 
complication rates and associated diseases amongst diabetes patients. Prevalence of 
diabetes in Malaysian National Health Morbidity Survey 111 (Zanariah et al., 2006) is 
14.9% compared with NHMS ІІ in 1996 which was 8.35 %. 
 
1.2 PATHOPHYSIOLOGY OF COMPLICATIONS OF TYPE 2 DIABETES 
 MELLITUS 
 
Diabetic complications can be classified broadly as microvascular or macrovascular 
disease. Microvascular complications include neuropathy (nerve damage), nephropathy 
(kidney disease) and vision disorders (e.g. retinopathy, glaucoma, cataract and corneal 
disease). Macrovascular complications include heart disease, stroke and peripheral 
vascular disease. Other complications of diabetes include infections, metabolic 
difficulties, impotence and autonomic neuropathy. 
 
Eighty percent of patients with diabetes mellitus die a thrombotic death. Seventy five 
percent of these deaths are due to cardiovascular complications, and the remainder is 
due to cerebrovascular events and peripheral vascular complications (Carr ME., 2001).  
 
Endothelial abnormalities, coagulation activation markers abnormalities, level of the 
anticoagulant protein abnormality, and increased platelet aggregation made a 
constellation of findings that supports the clinical observation that diabetes is a 
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hypercoagulable state. These changes favour the development of a hypercoagulable pro-
thrombotic state, which may in turn enhance cardiovascular risk by increasing the 
likelihood of developing an occlusive thrombus within an artery and contributing to the 
development of atherosclerotic lesions (Dunn and Grant, 2005). 
 
Endothelial dysfunction, present at disease onset, may be the risk of atherogenesis that 
is present throughout the course of diabetes and associated with late-stage adverse 
outcomes. Investigations have revealed that vascular endothelium, a crucial regulator of 
vascular homeostasis, participates importantly in the control of vascular tone and blood 
flow, coagulation and thrombosis, nutrient delivery and waste removal, inflammation, 
vascular smooth muscle cell growth and migration, leukocyte attraction and diapedesis 
(TJ.Anderson, 2003)  
 
The central pathological mechanism in macrovascular disease is the process of 
atherosclerosis, which leads to narrowing of arterial walls. Atherosclerosis results from 
chronic inflammation and injury to the arterial wall in the peripheral or coronary 
vascular system. In response to endothelial injury and inflammation, oxidised lipids 
from LDL particles accumulate in the endothelial wall of arteries. Monocytes infiltrate 
the arterial wall and differentiate into macrophages, which accumulate oxidised lipids to 
form foam cells. Once formed, foam cells stimulate macrophage proliferation and 
attraction of T-lymphocytes. T-lymphocytes, in turn, induce smooth muscle 
proliferation in the arterial walls and collagen accumulation. The net result of the 
process is the formation of a lipid-rich atherosclerotic lesion with a fibrous cap. Rupture 
of this lesion  leads to acute vascular infarction (PJ, 2007). 
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• Source : Cines DB et al., 1998 
 Figure 1.1  Endothelial Dysfunction in Diabetes Mellitus 
In diabetes, hyperglycaemia, excess free fatty acid release, and insulin resistance alters 
adverse metabolic events within the endothelial cell. Activation of these systems 
impairs endothelial function, augments vasoconstriction, increases inflammation, and 
promotes thrombosis. Decreasing nitric oxide and increasing endothelin- 1 and 
angiotensin II concentrations increase vascular tone and vascular smooth muscle cell 
growth and migration.  
 
Activation of the transcription factors nuclear factor kB (NF-kB) and activator protein 1 
induces inflammatory gene expression, with liberation of leukocyte-attracting 
chemokines, increased production of inflammatory cytokines, and augmented 
expression of cellular adhesion molecules.  
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Increased production of tissue factor and plasmin activator inhibitor 1 creates a 
prothrombotic milieu, while decreased endothelium derived nitric oxide and 
prostacyclin favours platelet activation (Carr ME., 2001).  
  
In addition to atheroma formation, there is strong evidence of increased platelet 
adhesion and hypercoagulability in type 2 diabetes. Impaired nitric oxide generation and 
increased free radical formation in platelets, as well as altered calcium regulation, may 
promote platelet aggregation.  
 
The platelet alterations that occur in diabetes have been extensively studied. An 
increased platelet aggregation has been reported in Type 1 (insulin-dependent) diabetic 
patients with poor metabolic control (Davis JW, 1982). Platelet hyperaggregation in 
diabetic patients is partly determined by an exaggerated ability of the platelets to bind 
both thromboxane  and fibrinogen  accompanied by a reduced binding capacity for 
prostacyclin and this can  also present in diabetic patients without vascular 
complications and in young diabetic patients (Collier A, 1986 ). 
 
Elevated levels of plasminogen activator inhibitor type 1 may also impair fibrinolysis in 
patients with diabetes (Carr M.E, 1991). Fibrinogen is a glycoprotein with a prolonged 
half-life. It can become hyperglycosylated circulates in an environment of containing 
high glucose, i.e., hyperglycemia in a poorly controlled diabetic. When such fibrinogen 
is clotted, the resulting fibrin structure is composed of small diameter fibers which are 
markedly resistant to degradation by plasmin. The higher the concentration of 
hyperglycosylated fibrinogen, the longer the clots take to dissolve. These results would 
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imply an increased resistance to fibrinolysis in poorly controlled diabetes (Carmassi, 
1992).  
 
The combination of increased coagulability and impaired fibrinolysis likely further 
increases the risk of vascular occlusion and cardiovascular events in type 2 diabetes 
(Beckman JA et al., 2002 ). 
 
1.3 DIABETES MELLITUS AND DISORDERS OF COAGULATION 
 
In normal situation coagulation begins almost instantly after an injury to the blood 
vessel has damaged the endothelium . Exposure of the blood to proteins such as tissue 
factor initiates changes to blood platelets and the plasma protein fibrinogen, a clotting 
factor. Platelets immediately form a plug at the site of injury; this is called primary 
hemostasis. Secondary hemostasis occurs simultaneously. Proteins in the blood plasma, 
called coagulation factors or clotting factors, respond in a complex cascade to form 
fibrin strands, which strengthen the platelet plug. 
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• Source : Hafer-Macko et al., 2002 
 Figure 1.2   The coagulation cascade - secondary haemostasis 
 
The coagulation cascade of secondary haemostasis has two pathways which lead to 
fibrin formation. These are known as the intrinsic pathway, and the extrinsic pathway. 
The primary pathway for the initiation of blood coagulation is the tissue factor pathway. 
The pathways are a series of reactions, in which a zymogen (inactive enzyme precursor) 
of a serine protease and its glycoprotein co-factor are activated to become active 
components that then catalyse the next reaction in the cascade, ultimately resulting in 
cross-linked fibrin. Coagulation factors are generally indicated by Roman numerals, 
with a lower case a appended to indicate an active form.  
 8 
Following damage to the blood vessel, factor VII (FVII) leaves the circulation and 
comes into contact with tissue factor (TF) forming an activated complex (TF-FVIIa). 
This TF-FVIIa activates factor IX (FIX) and factor X (FX). And then factor VII is itself 
activated by thrombin, activated factor XI (FXIa), factor XII (FXII) and activated FX. 
The activation of FX to form activated factor X (FXa) by TF-FVIIa is almost 
immediately inhibited by tissue factor pathway inhibitor (TFPI). 
 
FXa and its co-factor, activated factor V (FVa) form the prothrombinase complex, 
which activates prothrombin to thrombin. Thrombin then activates other 
components of the coagulation cascade, including FV and FVIII (which 
activates FXI, which, in turn, activates FIX), and activates and releases 
FVIII from being bound to Von Willebrand factor (vWF). Activated factor VIII 
is the co-factor of activated factor IX, and together they form the "tenase" complex, 
which activates FX; and so the cycle continues. ("Tenase" is a contraction of "ten" and 
the suffix "-ase" used for enzymes.). 
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• Source: Mark A. Creager et al., 2003 
 
 Figure 1.3  Schematic of coagulation disorder in Diabetes compared to 
    normal homeostasis. 
 
Numerous epidemiological studies have concurred in recognizing fibrinogen as having 
an important predictive value as a marker of cardiovascular risk (Wilhelmsen L, 1984). 
Studies in diabetic patients also showed increase plasma level of plasminogen (Oanda 
OP, 1992). 
Epidemiological studies also have reported that high levels of factor VII are associated 
with a high mortality rate for cardiovascular events it have also been reported in 
diabetes (Balleisen L, 1985).  
In fact, in one of a study in normal subjects, a direct correlation has been reported 
between levels of factor VII and fasting glycaemia. This demonstrated that glycaemia 
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levels can directly affect the concentrations of factor VII in both diabetic patients and 
normal subjects (Ceriello A, 1988). 
Another factor of coagulation that alters with hyperglycaemic state is factor X. The 
antigenic levels of factor X are increased but the activation of this factor is however 
reduced by the induction of hyperglycaemia, which has been observed both in diabetic 
patients and also in normal subjects (Ceriello A et al., 1990).  
Erythrocytes also play a important role in coagulation processes. When the erythrocyte 
membrane is impaired, ADP is released, stimulating platelet aggregation. In diabetes, 
the erythrocytes are damaged, resulting in reduced half-life, resulting in polycythaemia 
and increased volume (Jones RL, 1981). These factors may then cause blood 
hyperviscosity with a consequent increase in thrombotic risk. 
 
1.4 COAGULATION INHIBITORS IN DIABETES MELLITUS 
 
Since the action of thrombin is the result of a balance between the pro-coagulant 
cascade and the action of the various inhibitors on it or on its production, it is 
reasonable to assume that these inhibitors may also play an important role in the genesis 
of thrombophilia state in diabetes. 
There are several mechanisms that keep the coagulation cascade in check. One of the 
major physiological anticoagulant is protein C. It is a vitamin K-dependent serine 
protease enzyme produced by hepatocytes that is activated by thrombin into activated 
protein C (APC). Protein C is activated in a sequence that starts with Protein C and 
thrombin binding to a cell surface protein thrombomodulin. Thrombomodulin binds 
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these proteins in such a way that it activates Protein C. The activated form, along with 
protein S and phospholipids as cofactors, degrades activated factor V and activated 
factor VIII.  
If there is not enough protein C or protein S, or if either one is not functioning normally, 
the thrombin generation goes on largely unchecked. This can lead to excessive or 
inappropriate clotting that may block the flow of blood and cause thrombosis. Tests for 
protein C and protein S may look at their function (activity) or quantity (antigen). 
Functional tests for protein C and protein S are usually ordered, along with other tests 
for hypercoagulability, to screen for sufficiency, normality, and factor activity.  
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• Source: Ceriello A et al., 1995 
 
Figure 1.3 Schematic of the normal biological   anticoagulant   
  mechanisms.  
 
Panel A : Antithrombin III control of the serine protease clotting factors.  
Panel B : The proteins C and S system for control of the non-serine clotting 
     factors Va and VIIIa.  
Panel C : Control of factor VIIa by TFPI. 
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Based on the results, quantities of protein C antigen and free, or sometimes total, protein 
S antigen may be measured to look for decreased production due to an acquired or 
inherited condition and to classify the type of deficiency. Acquired protein C 
deficiency may be caused by large blood clots, liver disease, disseminated intravascular 
coagulation (DIC), infection (sepsis), and vitamin K deficiency. Treatment with 
warfarin or certain types of chemotherapy can also cause acquired protein C deficiency. 
If the shortage is due to a rare inherited genetic change, the quantity of protein C or 
protein S available and the degree of activity can be used to help determine whether a 
person is heterozygous or homozygous for the mutation. 
 
Functional tests for protein C and protein S measure their activity and evaluate their 
ability to regulate and slow blood clotting. Decreased activity may be due to a decreased 
concentration of protein C or S or, more rarely, due to dysfunctional protein C or S. 
 
To look for Protein C and protein S quantity, antigen tests measure the amount of the 
protein present. Protein S works with protein C. It is present in the blood in two forms, 
free or bound to another protein, but only the free form is available to combine with 
protein C. Protein S antigen tests measure either free protein S or total protein S. 
 
If both the activity and the concentrations of protein C and protein S antigens are 
normal, it usually indicates adequate clotting regulation. Low level of protein C or 
protein S activity can result in excessive or inappropriate blood clotting. If the protein is 
dysfunctional (normal levels of protein, but it does not work correctly), the coagulation 
process will not be sufficiently regulated. Either situation can lead to an increased risk 
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of developing a clot that blocks the flow of blood in the veins, but the severity of the 
risk depends on the magnitude of the deficiency and/or the degree of dysfunction of the 
protein. The normal values of activity are 60 % to 150 % inhibition. 
 
In diabetes, abnormalities of hemostasis have been reported in many studies over almost 
thirty years, but unfortunately the results have often appeared contradictory. The 
hemostatic alterations could lead to increased risk of vascular disease in diabetic 
patients. In one study, plasma coagulation factors (e.g., factor VII and thrombin) and 
lesion-based coagulants, tissue factor are found to be increased, and endogenous 
anticoagulants (e.g., thrombomodulin and protein C) are decreased (Hafer-Macko et al., 
2002, Ceriello A et al., 1990, Ceriello A et al., 1995).  
 
In another study, they evaluated some coagulation factors (Fibrinogen, Factor II, Factor 
VII) and coagulation inhibitors (Protein C, Protein S), and plasminogen in fifty-four 
type 2 diabetic patients. They analyzed the possible relationship between coagulation 
factors and coagulation inhibitors and parameters for glyco-metabolic control 
(glycosylated haemoglobin, fructosamine) and disturbed lipid metabolism (cholesterol, 
triglycerides). The results showed increase of fibrinogen, correlated with the metabolic 
control of the disease, positive correlation between plasminogen, factor II, protein S and 
hypertriglycerides, decreased levels of protein C correlated neither with metabolic 
control of disease neither with disturbed lipid metabolism (Moccia F, 1996). 
 
Another one most studied coagulation inhibitors is antithrombin 111(ATIII). A decrease 
in the biological activity of this molecule in the presence of a normal antigenic 
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concentration has been found in diabetic patients. In this case as well, hyperglycaemia 
seems capable of directly affecting the activity of the molecule, in both diabetic patients 
and in normal subjects (Ceriello A, 1983). 
 
The effect of glycaemia on ATIII may have an important pro-thrombotic impact. In fact, 
the decreased in its biological activity results in a reduced thrombin-antithrombin 
complex formation with consequent hyperactivity of the thrombin and improvement in 
metabolic control e.g. insulin therapy, can increase the activity of the molecule (Husted 
SE, 1989). 
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1.5 INTRODUCTION TO TRADITIONAL MEDICINE AND DIABETES 
 
Traditional medicine, also known as complementary medicine or alternative medicine 
provides the first line of primary health-care to major segments of the population throughout 
the world. Traditional medicine has been defined by the World Health Organization (WHO) 
as “health practices, approaches, knowledge and beliefs incorporating plant, animal and 
mineral-based medicines, spiritual therapies, manual techniques and exercises, applied 
singularly or in combination, to treat, diagnose and prevent illnesses or maintain well-being” 
(WHO, 2003).  
 
About 25% of the drugs used in modern medicine owe their origins to plants from tropical 
rainforests (S.Elliot., 1986). In fact, many drugs listed as conventional medications now were 
also originally derived from plants; for example, salicylic acid, a precursor of aspirin, was 
originally derived from white willow bark and the meadowsweet plant whereas vincristine, 
used to treat certain types of cancer, comes from periwinkle.  
 
One condition for which minority populations are likely to use complementary and 
alternative medicine therapies is diabetes. This is particularly prevalent in many minority 
cultures have a long history of using herbal preparations to treat diabetes, and recent research 
suggests that some herbal therapies may have a role in the treatment of this complex disease 
(Berman, 1999).  
 
In Malaysia, the prevalence of herbal medicines use is high (Aziz Z., 2009). Reasons for the 
use of herbals include  that it is part of the culture and belief of some people for maintenance 
of health or to treat certain ailments, relatively cheaper cost of herbal products and hence 
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affordability to the lower income group as well as herbals are  natural and that anything 
natural is safe (Hussin, 2001).  
 
In another  study done by the  School of Pharmacy, International Medical University among 
patients in their outpatients clinic, this showed that a high percentage of alternative 
medication including herbal was used, this included of 24.6 percent among patients with 
chronic diseases especially in  diabetes patients (35.5%) (Syed Shahzad Hasan et al., 2009). 
 
In a study carried out locally at Hospital Tuanku Jaafar, Seremban, they aimed to evaluate 
complementary and alternative medicine (CAM) usage among their diabetic patients. From 
their study, the herbal drugs (64.9%) were the most common type of CAM utilised by the 
patients followed by vitamins (57.9%), ginseng (12.3%), and yoga (7.9%).  This study 
confirms an overall of a high frequency of CAM use (49.6%) among diabetic patients 
(Shahazad Hasan, 2011). 
 
1.6 Andrographis paniculata (“Hempedu Bumi”) 
Andrographis paniculata (Acanthaceae) is a traditional medicinal plant common in south 
East Asia and found from India to Indo-china. Commonly called as king of bitter or kariyat, 
kalmegh, hempedu bumi and pokok cerita, it is an erect branch plant with green leaves and 
attained height of 60-70cm. The leaves and the aerial part of the plant have been used to cure 
various kinds of ailments.  
Some important chemical compounds have been isolated from parts of the plant. The aerial 
part contains several diterpenoids and diterpene glycosides. Its main constituent, 
andrographolide, a diterpene lactone, is mainly responsible for its bitter taste. From its leaves, 
the active ingredients are diterpene lactones, flavone derivatives such as oroxylin and 
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wogonin. The major constituents are diterpene lactones (free and in glycosidic forms) 
including andrographolide, deoxyandrographolide, 11,12-didehydro-14-
deoxyandrographolide, neoandrographolide, andrographiside, deoxyandrographiside and 
andropanoside. 
The various routes of administration of herbal medications are typically chosen according to 
both the consistency of the preparation and the disease or condition under treatment. The 
herbs available come in several different forms: teas, syrups, oils, liquid extracts, tinctures, 
and dry extracts (pills or capsules). When orally consumed, andrographolide appears to 
accumulate in organs throughout the viscera.  
Pharmacokinetics studies showed that andrographolide is quickly absorbed and extensively 
metabolised in rats and in human (Panossian et al., 2000). 90 percent is eliminated within 48 
- hour. Andrographolides are excreted fairly rapidly from the body via the urinary and 
gastrointestinal tract. Maximum plasma level were reach after 1.5 to 2 hours and the half life 
was 6.6 hours. The high pressure liquid chromatography (HPLC) is simple and rapid methods 
and can be use to determine concentration of active components in various extract of 
Andrographis paniculata.  
 
1.6.1 Medicinal usage of Andrographis paniculata  
 
Since ancient times, Andrographis paniculata has been used in traditional systems of 
medicine and some other countries for multiple clinical applications. Among the effects that 
have been proven by clinical trials are anti-inflammatory activities, anti-malarial activity, 
anti-fertility activity, hepatoprotective activity, immunological potential, respiratory system 
benefit, cardiovascular activity and hypoglycaemic activity.   
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In a study to determine the presence of antibacterial activity in the crude extracts of some of 
the commonly used medicinal plants in Malaysia, Andrographis paniculata was among five 
plants that were tested:  It showed antibacterial activities towards Pseudomonas  aeruginosa 
and being the most potent at minimum inhibitory concentration (MIC) of 2 g/disc (Zaidan et 
al., 2005, Mishra et al., 2009). In several other studies, extracts of Andrographis paniculata 
containing the active ingredients of deterpenoids were evaluated for antimalarial activity 
against Plasmodium berghei, one of the parasites that transmit malaria. The extract was found 
to produce considerable inhibition of parasite multiplication (Mishra et al., 2009). It has also 
amongst the strongest activity towards Brugia malayi species of filaria (Zaridah et al., 2001).  
 
Andrographis paniculata is also being studied to assess the efficacy of it in the symptomatic 
treatment of uncomplicated upper respiratory tract infection. These studies showed 
significant reduction in symptom severity (Poolsup et al., 2004, Gabrielian et al., 2002). The 
prevention of the common cold with an extract of Andrographis paniculata was also shown 
in a pilot double-blind study where subjects were given a formulation of Andrographis 
paniculata  and were diagnosed for the presence or absence of colds during a three-month 
period There was a significant decrease in the incidence of colds as compared to the placebo 
group who were not taking Andrographis paniculata formulation at the end of three months 
(Burgos et al., 2009). 
 
Andrographis paniculata also shows potent immunomodulatory and anti - angiogenic 
activities in tumour tissues. An in - vitro study (Varma et al., 2009) demonstrated the 
capability of a compound in Andrographis paniculata inducing cell-cycle arrest and 
apoptosis in a variety of cancer cells at different concentrations. The results of a study in 
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Japan demonstrated that Andrographis paniculata also had a potent cell differentiation-
inducing activity on leukaemia cells (Matsuda et al., 1994). 
The ability of Andrographis paniculata to lower fever has been demonstrated independently 
in several centres. Rat studies done in China have shown that andrographolide, 
neoandrographolide, and dehydroandrographolide can lower the fever produced by different 
fever-inducing agents, such as bacterial endotoxins (toxic chemicals released from bacteria), 
pneumococcus, haemolytic streptococcus, typhoid, paratyphoid, and the chemical 2,4-di-
nitro-phenol  (Madav. H.C, 1995). 
  
In India, a study was conducted to evaluate the effect of Andrographis paniculata  in 
infective hepatitis (Kapil A. et al., 1993).  There was marked improvement in term of appetite 
on the fifth day of treatment, jaundice gradually diminished and completely disappeared 
within 24 days, and fever subsided after 7 days on average with and improvement in liver 
function tests.  
Other medicinal usage of Andrographis paniculata or its active ingredients is anti fertility 
where in one of the study, it resulted in cessation of spermatogenesis, degenerative changes in 
the seminiferous tubules, regression of Leydig cells and regressive and/or degenerative 
changes in the epididymis, seminal vesicle, ventral prostate and coagulating gland of tested 
mice (Akbarsha et al., 1990, Zoha  M.S. et al., 1989).  
 
As a potential antiretroviral effect, in a phase one clinical trial, showed  a significant rise in 
the mean CD4  lymphocyte level of HIV subjects occurred after administration of 10 mg/kg  
andrographolide ,from a baseline of 405 cells/mm3 to 501 cells/mm3 (Carlo Calabress et al., 
2000). 
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1.6.2  Cardioprotective and homeostasis effects of Andrographis paniculata  
  
To date, there are not many studies exploring the direct effect of Andrographis paniculata on 
coagulation or fibrinolytic parameters. However, in one study, the active ingredient of 
Andrographis paniculata was investigated for its suggested influence on the platelet-
activating factor (PAF) which showed that andrographolide inhibits PAF-induced human 
blood platelet aggregation in a dose dependent manner. This result indicates that 
andrographolide has a mechanism of action associated with antithrombotic activity (Amroyan 
et al., 1999). 
 
The effect on platelet aggregation was also seen in another study where 63 patients with 
cardiac and cerebral vascular diseases were observed at 3 hours and/or one week after taking 
Andrographis paniculata extracts. Results showed that both 1 minute and 5 minutes platelet 
aggregation induced by adenosine diphosphate (ADP) were significantly inhibited. Serotonin 
release reaction from platelets was observed in 20 volunteers taking Andrographis 
paniculata. The observation also showed that Andrographis paniculata could inhibit the 
release of dense and alpha agranules from platelet and dilation of canalicular systems. All 
these findings might be due to the antiplatelet effect of Andrographis paniculata (Zhang et 
al., 1994). 
In another study, the three active diterpenoids from this plant, including aqueous plant 
extracts, were investigated for the inhibitory effect on platelet aggregation in vitro. Results 
indicate that andrographolide [Andrographis paniculata (1)] and 14-deoxy-11,12-
didehydroandrographolide [Andrographis paniculata (3)] significantly inhibited thrombin-
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induced platelet aggregation in a different concentration and time-dependent manner.. In 
addition, standardised aqueous extracts of Andrographis paniculata containing different 
amounts of Andrographis paniculata (3) inhibited thrombin-induced aggregation to different 
degrees. Therefore, the consumption of Andrographis paniculata products may help to 
prevent or treat some cardiovascular disorders for example, thrombosis (Thisoda et al., 2006). 
 
In experiments on dogs, the effect of Andrographis paniculata in alleviating the ischemia -
reperfusion injury was prominent. In this study, after treatment with Andrographis paniculata 
in the ischaemia group, superoxide dismutase (SOD) in the ischemic region of myocardial 
tissue in the ischemia - reperfusion group was significantly decreased and calcium of 
ischaemic region of myocardial cell was increased. In the Andrographis paniculata pre-
treated ischaemia - reperfusion group, on the contrary, all the above parameters were 
reversed. These findings indicate that Andrographis paniculata may improve the activity of 
sarcolemma adenosine triphospatase (ATPase) in alleviating the calcium and sodium 
overloading by decreasing the harmful effect of oxygen free radicals. Although the 
mechanism of action was not fully determined, it was concluded that Andrographis 
paniculata can be further be studied for the benefit of its antithrombotic activity (Guo et al., 
1994, Guo et al., 1995). 
 
A study conducted to determine the effect of Andrographis paniculata to the 
pharmacokinetics and pharmacodynamics of the anticoagulant warfarin in rats showed that 
the concomitant application of Andrographis paniculata and warfarin did not produce 
significant effects on the pharmacokinetics of warfarin, and practically no effect on its 
pharmacodynamics (Hovhannisyan et al., 2006). 
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In an experimental study on the search for effective herbal drugs to reduce restenosis 
incidence after coronary angioplasty, Andrographis paniculata was used in a study on 
atherosclerotic stenosis and restenosis after experimental angioplasty. Preliminary results 
showed that Andrographis paniculata can significantly alleviate an atherosclerotic iliac 
artery. A follow-up angiography 4 weeks after angioplasty in the same patients showed the 
dilated iliac arteries in the control group all had severe restenosis, but in the Andrographis 
paniculata group no or only mild re-stenosis occurs. These preliminary results suggest that 
Andrographis paniculata can significantly alleviate stenosis. The above findings conclude 
that Andrographis paniculata may play an important role as an antithrombotic agent in 
preventing re-stenosis after coronary angioplasty (Wang and Zhao, 1993). 
 
1.6.3  Hypoglycaemic effects of Andrographis Paniculata  
Presently, there is a growing interest in traditional herbal remedies due to the multiple 
reasons associated with oral hypoglycaemic agents from the disease sufferer for the treatment 
of diabetes mellitus. Several species of herbal plants have been described in the scientific and 
popular literature as having antidiabetic activity (Valiathan M.S, 1998).  
As for the situation in Malaysia, Malays believe that Andrographis paniculata can treat 
diabetes mellitus.  Local Malaysian study on screening for anti hyperglycaemia activity in 
several local herbs showed that a few of them showed significant blood glucose lowering 
effecs. In one study, aqueous extract of Andrographis paniculata caused significant reduction 
in blood glucose levels (Husen et al., 2004).  In this study, dried raw material with dose of 
50mg/kg body weight of Andrographis paniculata administered for 10 days has the highest 
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antihyperglycaemia activity among other herbs and this activity was enhanced when freeze 
dried extract was used. 
 
Regarding the antihyperglycaemia mechanism of Andrographis paniculata, previous studies 
have proposed several mechanisms. A study done to examine the effect of Andrographis 
paniculata on pancreatic β-cells showed that Andrographis paniculata was a very strong, 
dose dependent insulinotropic agent, glucose dependent and independent insulin secreting 
agent.  This study also conclude that Andrographis paniculata affected membrane receptors, 
mostly ATP - dependent potassium channels (Wibudi et al., 2008).  
In another study, the extract showed appreciable alpha-glucosidase inhibitory effect in a 
concentration-dependent manner, and a weak alpha - amylase inhibitory activity 
(Subramanian et al., 2008). In another animal study, oral administration of Andrographis 
Paniculata from aqueous extract of the leaves resulted in significant decrease in the blood 
glucose levels. A dose of 400 mg/kg two weeks duration lowered blood glucose level of 
streptozotocin- induced animals and increased activity of superoxide dismutase and catalase 
(Dandu and Inamdar, 2009). 
Later it was found that the chloroform fraction of the plant extract (1 g/kg) significantly 
reduced both the blood glucose level of normoglycaemic rats and during glucose tolerance 
tests. These results suggested that the antidiabetic component of the Andrographis paniculata 
were present in the chloroform fraction of the extract compared to aqueous extract of 
Andrographis paniculata (Subramanian et al., 2008). 
In another study by Asmawi, Andrographis paniculata ethanolic extract was evaluated to 
screen the effect on insulin resistance using a combination of fat-fed diet and low dose 
streptozotocin. Oral administration of 1000 mg/kg extract to rats was able to cause a 
